Lancet: Four-in-one blood pressure "quadruple pill" is more effective than monotherapy

The research results were published in The Lancet and presented at the Global ESC Cardiology Conference

The first large-scale, long-term trial of a new strategy, which uses a very low-dose combination in one capsule, has proven to significantly improve the control of high blood pressure-high blood pressure is the main cause of heart attacks and strokes

Hypertension is the number one killer in the world, but poor blood pressure control is still common

This is the first large-scale randomized controlled clinical trial that started this new combination antihypertensive drug.

Traditionally, doctors started using a drug and then continued to consider adding or changing treatment methods, but this strategy is often unsuccessful in practice, and the rate of blood pressure control has remained high for decades

The results of this Australian study were published in The Lancet on August 28, 2021, and will be presented at the world's leading European Society of Cardiology Conference (ESC Conference 2021)

Professor Clara Chow, director of the Westmead Center for Applied Research at the University of Sydney and lead author, said in another review in The Lancet this week that the control of high blood pressure is not ideal anywhere

Professor Chow said: "Statistics on the global burden of high blood pressure this week show that cases of high blood pressure have doubled in the past three decades

Dr.

A multi-center clinical trial in Australia showed that a quadruple-dose hypertension treatment drug (QUARTET) containing four drugs is a potential future "quadruple-dose" therapeutic drug.

The study was funded by the National Health and Medical Research Council and recruited 591 hypertensive patients in 10 centers in Australia.

Professor Anthony Rodgers, senior author at the George Institute of the University of New South Wales in Sydney and Imperial College London, said: "Our trials have overwhelmingly demonstrated the effectiveness, resistance and safety of this ultra-low-dose combination strategy.

Professor Chow said that this study is based on their previous study comparing quadpill and placebo methods

"This is the first study to show that this benefit can be maintained for a long time without diminishing over time

Global practice

Professor Chow said that there are still some important research questions

In addition, just like the recent hypertension guidelines issued in Europe, the United States and elsewhere, the hypertension guidelines issued by the WHO this week also recommend that most patients start taking two antihypertensive drugs instead of one

There is also a major research translation challenge in the future: "These strategies will have a significant impact on global health only when the patients most in need can access and can afford them," said Professor Chow
.

"When we discover such effective, simple and safe treatments, we must do our best to get them to those who benefit the most
.
"

Professor Chow said that a simple and effective combination of four drugs strategy may affect the lives of people all over the world
.
She concluded: "Globally, hypertension is the leading cause of preventable deaths-we hope that our world-leading research results can quickly be transformed into a product that can be used by the public
.
"